Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Commission has approved Wyeth's Torisel for the first-line treatment of patients with advanced renal cell carcinoma who have at least three of six prognostic risk factors.
Subscribe to our email newsletter
Torisel (temsirolimus) specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an important regulator of cell proliferation, cell growth and cell survival.
Robert Ruffolo, Jr., president of Wyeth Research and senior vice president of Wyeth, said: “The European Commission’s approval of Torisel underscores the importance of this therapy for patients with advanced kidney cancer and reinforces the potential of this mechanism of action as a new approach in oncology.”